Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH (DIM)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : and Penn State partner to advance teaching, research in biotechnology

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2018 | 07:34am EST

Sartorius Stedim Biotech and Penn State University have entered into a collaborative partnership to advance multidisciplinary teaching and research in biotechnology. This long-term relationship will support the education and preparation of the next generation of biotechnology leaders. Part of Sartorius investment will be to enhance the Fermentation Facility that will play a significant role in Penn States Center of Excellence in Industrial Biotechnology (CoEIB). Sartorius will provide state-of-the-art fermentation technologies, and a central laboratory within the Fermentation Facility will be named the Sartorius Fermentation Gallery.

We are grateful to Sartorius for their commitment to and investment in biotechnology at Penn State, said O. Richard Bundy III, Penn States vice president for development and alumni relations. Sartorius is a global leader in research and manufacturing technologies in the field of biotechnology. Their support will enable Penn State to provide an environment that closely matches what is available in todays premier research and manufacturing facilities, further elevating the Universitys leadership position in this rapidly growing field.

Sartorius views this partnership as an opportunity to create a hub that will promote innovation in biotechnology. We look forward to bringing together future thought leaders within the new Sartorius Fermentation Gallery, said Reinhard Vogt, member of Executive Committee of Sartorius Stedim Biotech. The innovative bioanalytical and bioprocess technologies of Sartorius will enable these scientists to accelerate progress in biotechnology.

Sartorius, together with additional industry partners, has been supporting Penn State for more than a year in designing the new lab space and in equipping it based on the latest technologies.

The Fermentation Facility is one of ten core facilities in the Huck Institutes of the Life Sciences and the cornerstone of Penn States comprehensive biotechnology effort. This effort includes the CoEIB, recently launched with a landmark gift from CSL Behring. The CoEIB provides a focal point for Penn States programs in the area of industrial biotechnology, including the development of research and educational initiatives focused, among other areas, on biopharmaceutical manufacturing, i.e., the manufacture of medical drugs from biological sources.

Biotechnology has implications for the medicines we take, the food we eat, the fuel we fill our cars with, and more, but researchers working and students training in this area require world-class facilities and equipment in order to move this field forward, said Peter Hudson, director of the Huck Institutes of the Life Sciences and Willaman Professor of Biology. I am grateful to Sartorius for providing state-of-the-art equipment that will drive innovation for years to come.

Underpinning the growth and sustainability of the CoEIBs vision, as well as its contribution to the future of industrial biotechnology, is the active participation of alumni, friends, and corporate and foundation partners.

(c) 2018 Arab Times Kuwait English Daily. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SARTORIUS STEDIM BIOTECH
01/02SARTORIUS STEDIM BIOTECH SA : Annual report of the liquidity contract with the s..
EQ
2018SARTORIUS STEDIM BIOTECH : France‘s ambassador Descôtes visits Sartorius S..
PU
2018SARTORIUS STEDIM BIOTECH : SSB enters into collaboration with Immunochina to dev..
AQ
2018SARTORIUS STEDIM BIOTECH : Lonza and Sartorius Stedim Biotech modify relationshi..
AQ
2018SARTORIUS STEDIM BIOTECH : Genedata Licenses its Bioprocess Software Platform to..
AQ
2018GLOBAL MARKETS LIVE : Verizon, McDonald’s, 3M, Renault, Essilor, Atos...
2018SARTORIUS STEDIM BIOTECH SA : quaterly earnings release
2018SARTORIUS STEDIM BIOTECH : and Repligen collaborate on perfusion-enabled bioreac..
AQ
2018SARTORIUS STEDIM BIOTECH : and Repligen collaborate to create novel perfusion-en..
AQ
2018SARTORIUS STEDIM BIOTECH : and Repligen collaborate on perfusion enabled bioreac..
AQ
More news
Financials (€)
Sales 2018 1 213 M
EBIT 2018 278 M
Net income 2018 195 M
Debt 2018 129 M
Yield 2018 0,60%
P/E ratio 2018 41,73
P/E ratio 2019 36,35
EV / Sales 2018 6,89x
EV / Sales 2019 6,16x
Capitalization 8 232 M
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS STEDIM BIOTECH
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 108 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Liliane de Lassus Independent Non-Executive Director
Bernard Lemaître Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH1.37%9 359
MEDTRONIC PLC-4.18%116 845
BAXTER INTERNATIONAL5.80%37 069
HOYA CORPORATION-3.56%21 820
TERUMO CORP3.80%21 496
ZIMMER BIOMET HOLDINGS1.02%21 197